Form 4: Aspen Aerogels Grants Equity to CAO Glenn Deegan

Aspen Aerogels, Inc. reported an equity grant to its Chief Administrative Officer, General Counsel, and Corporate Secretary, Glenn E. Deegan, consisting of 55,503 Restricted Stock Units and 75,171 stock options.

Summary

• Glenn E. Deegan, Chief Administrative Officer, General Counsel, and Corporate Secretary of Aspen Aerogels, Inc. (ASPN), received equity awards.
• The awards include 55,503 Restricted Stock Units (RSUs) and 75,171 stock options.
• The RSUs represent the right to receive one share of Common Stock upon vesting, with a transaction price of $0.
• The stock options have an exercise price of $3.35 per share.
• Both the RSUs and stock options vest in three equal annual installments: one-third on March 4, 2027, an additional one-third on March 4, 2028, and the final one-third on March 4, 2029.
• The stock options have an expiration date of March 4, 2036.
• Following these transactions, Deegan beneficially owns 67,176 RSUs and 75,171 stock options.
• A Power of Attorney was granted by Glenn Deegan to Andrew Lauzon, Senior Director, Total Rewards, on September 22, 2025, to facilitate SEC filings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value and executive retention.

Positives

• The equity grant aligns management's interests with those of shareholders, incentivizing long-term performance.
• The multi-year vesting schedule encourages retention of a key executive over a three-year period.

Negatives

• No direct negatives are apparent from this routine insider compensation disclosure.

Future Outlook

The vesting schedule for the granted Restricted Stock Units and stock options extends through March 4, 2029, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that equity grants to key executives are a standard practice across industries, particularly in technology and materials sectors like Aspen Aerogels, to align executive incentives with long-term shareholder value creation and to retain talent. The structure of these awards, with multi-year vesting, is typical for executive compensation packages.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options with a multi-year vesting schedule is a common compensation practice for senior executives in publicly traded companies, comparable to practices at peers in the advanced materials or industrial technology sectors.
• The exercise price of $3.35 for the options would typically be set at the market price on the grant date, which is standard for incentive stock options.
• The 10-year expiration period for stock options (until March 4, 2036) is also a common duration for such awards.

Corporate Governance

Related Party Transactions

• The equity grant to Glenn E. Deegan, a key executive, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the executive's financial interests with shareholder value creation, potentially leading to improved long-term performance. Dilution from the issuance of shares upon vesting/exercise is a consideration.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.
• Management: Provides significant long-term incentives and compensation to a key executive, aiding in retention and motivation.

Next Steps

• Vesting of one-third of RSUs and stock options on March 4, 2027.
• Vesting of an additional one-third of RSUs and stock options on March 4, 2028.
• Vesting of the final one-third of RSUs and stock options on March 4, 2029.
• Potential exercise of stock options by Glenn E. Deegan before March 4, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a senior executive, which is a standard practice for executive compensation and retention. It does not present new information that would fundamentally alter the investment thesis for Aspen Aerogels, thus a 'hold' recommendation is appropriate for existing investors. New investors should consider broader company fundamentals beyond this compensation disclosure.

Keywords

Aspen Aerogels, ASPN, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Glenn Deegan, Executive Compensation, Corporate Governance